- $11.87m
- -$11.39m
- $1.98m
Lipocine Inc reports results for the quarter ended in December - Earnings Summary
Lipocine Inc expected to post a loss of 3 cents a share - Earnings Preview
Brief: Lipocine Completes Enrollment Of Lpcn 1148 Phase 2 Study For Decompensated Cirrhosis
Brief: Lipocine-On Dec 6, 2022 Co Received Notification From Nasdaq Indicating Will Have Additional 180-Day Grace Period,Until June 5,2023,To Regain Compliance
Brief: Lipocine Announces Financial Results For The Third Quarter
Lipocine Inc reports results for the quarter ended in September - Earnings Summary
Lipocine Inc expected to post a loss of 3 cents a share - Earnings Preview
Brief: Lipocine Appoints Spyros Papapetropoulos As Lead Director And Chairman Of Board
NASH treatment developers gain as rival fails in trial
U.S. STOCKS ON THE MOVE-Digital World Acquisition, Carnival, Crypto stocks
U.S. STOCKS ON THE MOVE-Arcutis Biotherapeutics, Chegg, Li Auto
Lipocine rises on plans to cut spend on some drugs
Brief: Lipocine Announces Strategic Realignment And Forward Focus On Treating CNS Disorders
Brief: Lipocine Announces Favorable Regulatory Pathway On Oral LPCN 1154
Brief: Lipocine Inc - Announces Favorable Regulatory Pathway On Oral LPCN 1154 For Post-Partum Depression (PPD)
Lipocine Inc reports results for the quarter ended in June - Earnings Summary
Brief: Lipocine Inc - Reported A Net Loss Of $2.6 Million, Or $0.04 Per Diluted Share For Quarter Ended June 30, 2022
Brief: Lipocine Says FDA Clears LPCN 2101 IND For Adult Epilepsy Treatment
Brief: Lipocine Inc - On June 24, 2022, Antares Informed Co Of Its Decision Not To Exercise Their Option To License Tlando XR